HRP20131047T1 - Identifikacija antigena povezanih s tumorom za dijagnozu i lijeäśenje - Google Patents

Identifikacija antigena povezanih s tumorom za dijagnozu i lijeäśenje Download PDF

Info

Publication number
HRP20131047T1
HRP20131047T1 HRP20131047TT HRP20131047T HRP20131047T1 HR P20131047 T1 HRP20131047 T1 HR P20131047T1 HR P20131047T T HRP20131047T T HR P20131047TT HR P20131047 T HRP20131047 T HR P20131047T HR P20131047 T1 HRP20131047 T1 HR P20131047T1
Authority
HR
Croatia
Prior art keywords
nucleic acid
tumor
associated antigen
cancer
antibody
Prior art date
Application number
HRP20131047TT
Other languages
English (en)
Inventor
Ugur Sahin
Özlem TÜRECI
Michael Koslowski
Dirk Usener
Original Assignee
Ganymed Pharmaceuticals Ag
Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Ag, Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten filed Critical Ganymed Pharmaceuticals Ag
Publication of HRP20131047T1 publication Critical patent/HRP20131047T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Claims (22)

1. Farmaceutska kompozicija, koja sadrži jednu ili više komponenti izabranih iz grupe koju čine: (i) antitijelo koje se veže za ekstracelularni dio antigena koji je povezan sa tumorom, (ii) antisens nukleinska kiselina koja se hibridizira specifično sa nukleinskom kiselinom koja kodira antigen povezan sa tumorom, i (iii) siRNK usmjerena protiv nukleinske kiseline koja kodira antigen povezan sa tumorom, pri čemu navedeni antigen povezan sa tumorom ima sekvencu kodiranu nukleinskom kiselinom koja je izabrana iz grupe koju čine: (a) nukleinska kiselina koja sadrži nukleinsko kiselinsku sekvencu SEQ ID NO: 1, (b) nukleinska kiselina koja hibridizira sa nukleinskom kiselinom iz (a) pod vrlo specifičnim uvjetima, (c) nukleinska kiselina koja je degenerirana s obzirom na nukleinsku kiselinu pod (a) ili (b), i (d) nukleinska kiselina koja je najmanje 95% identična sa nukleinskom kiselinom pod (a), (b) ili (c) za uporabu u postupku za liječenje ili prevenciju kancera naznačenog ekspresijom antigena koji je povezan sa tumorom.
2. Farmaceutska kompozicija prema patentnom zahtjevu 1 za uporabu u postupku za liječenje ili prevenciju kancera naznačenog ekspresijom antigena povezanog sa tumorom prema patentnom zahtjevu 1, gdje je antitijelo monoklonalno, himerno ili humanizirano antitijelo, ili je fragment antitijela.
3. Farmaceutska kompozicija prema patentnom zahtjevu 1 ili 2 za uporabu u postupku za liječenje ili prevenciju kancera naznačenog ekspresijom antigena povezanog sa tumorom prema patentnom zahtjevu 1, gdje je antitijelo spojeno za terapeutsko ili dijagnostičko sredstvo.
4. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-3 za uporabu u postupku za liječenje ili prevenciju kancera naznačenog ekspresijom antigena povezanog sa tumorom prema patentnom zahtjevu 1, gdje je kancer – tumor pluća, tumor dojke, tumor prostate, melanom, tumor debelog crijeva, tumor želuca, tumor pankreasa, ORL tumor, karcinom renalnih stanica ili karcinom grlića materice, karcinom debelog crijeva ili karcinom dojke.
5. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-4 za uporabu u postupku za liječenje ili prevenciju kancera naznačenog ekspresijom antigena povezanog sa tumorom prema patentnom zahtjevu 1, gdje antigen povezan sa tumorom sadrži aminokiselinsku sekvencu izabranu iz grupe koju čine SEQ ID NOs: 2 i 7-11.
6. In vitro postupak za dijagnostificiranje ili praćenje bolesti kancera naznačene ekspresijom antigena povezanog sa tumorom, pri čemu taj postupak sadrži detekciju ili određivanje količine (i) nukleinske kiseline koja kodira antigen povezan sa tumorom, i/ili (ii) antigena povezanog sa tumorom, u biološkom uzorku izoliranom iz pacijenta, pri čemu navedeni antigen povezan sa tumorom ima sekvencu koju kodira nukleinska kiselina koja je izabrana iz grupe koju čine: (a) nukleinska kiselina koja sadrži nukleinsko kiselinsku sekvencu SEQ ID NO: 1, (b) nukleinska kiselina koja hibridizira sa nukleinskom kiselinom iz (a) pod vrlo specifičnim uvjetima, (c) nukleinska kiselina koja je degenerirana s obzirom na nukleinsku kiselinu pod (a) ili (b), i (d) nukleinska kiselina koja je najmanje 95% identična sa nukleinskom kiselinom pod (a), (b) ili (c).
7. Postupak prema patentnom zahtjevu 6, u kojem detekcija ili određivanje količine sadrži (i) dovođenje u kontakt biološkog uzorka sa sredstvom koje se vezuje specifično za nukleinsku kiselinu koja kodira antigen povezan sa tumorom ili za navedeni antigen povezan sa tumorom i (ii) detekciju formiranja ili određivanje količine kompleksa između sredstva i nukleinske kiseline ili antigena koji je povezan sa tumorom.
8. Postupak prema patentnom zahtjevu 7, naznačen time što je sredstvo koje se vezuje specifično za nukleinsku kiselinu koja kodira antigen povezan sa tumorom – oligonukleotid ili polinukleotid, koji specifično hibridizira sa navedenom nukleinskom kiselinom.
9. Postupak prema patentnom zahtjevu 7, naznačen time što je sredstvo koje se vezuje specifično za antigen povezan sa tumorom - antitijelo koje se specifično veže za navedeni antigen povezan sa tumorom.
10. Postupak prema bilo kojem od patentnih zahtjeva 6 do 9 naznačen time što navedeno praćenje navedene bolesti kancera sadrži određivanje regresije, toka ili početka navedene bolesti u uzorku od pacijenta koji ima navedenu bolest ili za koga se sumnja da se razboljeva od navedene bolesti.
11. Postupak prema patentnom zahtjevu 10, naznačen time što sadrži detekciju ili određivanje količine u prvom uzorku u prvoj vremenskoj točki i u drugom uzorku u drugoj vremenskoj točki i usporedbu dva uzorka.
12. Postupak prema bilo kojem od patentnih zahtjeva 7-11, naznačen time što je sredstvo obilježeno na detektabilni način.
13. Postupak prema bilo kojem od patentnih zahtjeva 6-12, naznačen time što uzorak sadrži tjelesnu tekućinu i/ili tjelesno tkivo.
14. Postupak prema bilo kojem od patentnih zahtjeva 6-13, naznačen time što antigen povezan sa tumorom sadrži aminokiselinsku sekvencu izabranu iz grupe koju čine SEQ ID NOs: 2 i 7-11.
15. Antitijelo za uporabu u postupku za liječenje, prevenciju, dijagnostificiranje ili praćenje bolesti kancera naznačene ekspresijom antigena povezanog sa tumorom, pri čemu navedeni antigen povezan sa tumorom ima sekvencu kodiranu od strane nukleinske kiseline koja je izabrana iz grupe koju čine: (a) nukleinska kiselina koja sadrži nukleinsko kiselinsku sekvencu SEQ ID NO: 1, (b) nukleinska kiselina koja hibridizira sa nukleinskom kiselinom iz (a) pod vrlo specifičnim uvjetima, (c) nukleinska kiselina koja je degenerirana s obzirom na nukleinsku kiselinu pod (a) ili (b), i (d) nukleinska kiselina koja je najmanje 95% identična sa nukleinskom kiselinom pod (a), (b) ili (c), pri čemu se antitijelo vezuje za ekstracelularni dio navedenog antigena povezanog sa tumorom i spojeno je sa terapeutskim ili dijagnostičkim sredstvom.
16. Antitijelo prema patentnom zahtjevu 15 za uporabu u postupku za liječenje, prevenciju, dijagnostificiranje ili praćenje bolesti kancera naznačene ekspresijom antigena povezanog sa tumorom prema patentnom zahtjevu 15, koje je monoklonalno, himerno ili humanizirano antitijelo, ili je fragment antitijela.
17. Antitijelo prema patentnom zahtjevu 15 ili 16 za uporabu u postupku za liječenje, prevenciju, dijagnostificiranje ili praćenje bolesti kancera naznačene ekspresijom antigena povezanog sa tumorom prema patentnom zahtjevu 15, pri čemu antigen povezan sa tumorom sadrži aminokiselinsku sekvencu izabranu iz grupe koju čine SEQ ID NOs: 2 i 7-11.
18. Antitijelo prema bilo kojem od patentnih zahtjeva 15, 16 ili 17 za uporabu u postupku za liječenje, prevenciju, dijagnostificiranje ili praćenje bolesti kancera naznačene ekspresijom antigena povezanog sa tumorom prema patentnom zahtjevu 15, u kojem je terapeutsko ili dijagnostičko sredstvo – toksin.
19. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-5 za uporabu u postupku za liječenje ili prevenciju kancera naznačenog ekspresijom antigena povezanog sa tumorom prema patentnom zahtjevu 1 za inhibiciju razvoja kancera kod pacijenta, pri čemu se farmaceutska kompozicija primjenjuje u efikasnoj količini.
20. Konjugat između antitijela i terapeutskog ili dijagnostičkog sredstva, gdje se antitijelo veže specifično za ekstracelularni dio proteina ili polipeptida, pri čemu je navedeni protein ili polipeptid kodiran od strane nukleinske kiseline izabrane iz grupe koju čine: (a) nukleinska kiselina koja sadrži nukleinsko kiselinsku sekvencu SEQ ID NO: 1, (b) nukleinska kiselina koja hibridizira sa nukleinskom kiselinom iz (a) pod vrlo specifičnim uvjetima, (c) nukleinska kiselina koja je degenerirana s obzirom na nukleinsku kiselinu pod (a) ili (b), i (d) nukleinska kiselina koja je najmanje 95% identična sa nukleinskom kiselinom pod (a), (b) ili (c) za uporabu u liječenju, prevenciji, dijagnostificiranju ili praćenju bolesti kancera naznačene ekspresijom proteina ili polipeptida.
21. Konjugat prema patentnom zahtjevu 20 za uporabu u postupku za liječenje, prevenciju, dijagnostificiranje ili praćenje bolesti kancera naznačene ekspresijom proteina ili polipeptida prema patentnom zahtjevu 20, u kojem je terapeutsko ili dijagnostičko sredstvo - toksin.
22. Uporaba kompleta za in vitro dijagnostificiranje bolesti kancera naznačene ekspresijom antigena povezanog sa tumorom, pri čemu komplet sadrži sredstva za detekciju ili određivanje količine (i) nukleinske kiseline koja kodira antigen povezan sa tumorom, i/ili (ii) antigena povezanog sa tumorom, u biološkom uzorku izoliranom iz pacijenta, pri čemu navedeni antigen povezan sa tumorom ima sekvencu koju kodira nukleinska kiselina koja je izabrana iz grupe koju čine: (a) nukleinska kiselina koja sadrži nukleinsko kiselinsku sekvencu SEQ ID NO: 1, (b) nukleinska kiselina koja hibridizira sa nukleinskom kiselinom iz (a) pod vrlo specifičnim uvjetima, (c) nukleinska kiselina koja je degenerirana s obzirom na nukleinsku kiselinu pod (a) ili (b), i (d) nukleinska kiselina koja je najmanje 95% identična sa nukleinskom kiselinom pod (a), (b) ili (c).
HRP20131047TT 2005-09-12 2013-11-05 Identifikacija antigena povezanih s tumorom za dijagnozu i lijeäśenje HRP20131047T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20050019786 EP1762575A1 (en) 2005-09-12 2005-09-12 Identification of tumor-associated antigens for diagnosis and therapy
PCT/EP2006/008695 WO2007031222A2 (en) 2005-09-12 2006-09-06 Identification of tumor-associated antigens for diagnosis and therapy

Publications (1)

Publication Number Publication Date
HRP20131047T1 true HRP20131047T1 (hr) 2013-12-06

Family

ID=35285406

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20131047TT HRP20131047T1 (hr) 2005-09-12 2013-11-05 Identifikacija antigena povezanih s tumorom za dijagnozu i lijeäśenje
HRP20150432TT HRP20150432T1 (hr) 2005-09-12 2015-04-21 Indentifikacija antigena povezanih s tumorom za dijagnozu i terapiju
HRP20180507TT HRP20180507T1 (hr) 2005-09-12 2018-03-27 Identifikacija antigena povezanih s tumorom za dijagnozu i terapiju

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20150432TT HRP20150432T1 (hr) 2005-09-12 2015-04-21 Indentifikacija antigena povezanih s tumorom za dijagnozu i terapiju
HRP20180507TT HRP20180507T1 (hr) 2005-09-12 2018-03-27 Identifikacija antigena povezanih s tumorom za dijagnozu i terapiju

Country Status (21)

Country Link
US (5) US20090202530A1 (hr)
EP (14) EP1762575A1 (hr)
JP (5) JP6037593B2 (hr)
KR (2) KR101359697B1 (hr)
CN (1) CN101305020B (hr)
AU (1) AU2006291717B2 (hr)
BR (1) BRPI0616827A2 (hr)
CA (2) CA2820201C (hr)
CY (3) CY1114661T1 (hr)
DK (3) DK1924600T3 (hr)
ES (4) ES2434945T3 (hr)
HK (3) HK1168608A1 (hr)
HR (3) HRP20131047T1 (hr)
HU (1) HUE037307T2 (hr)
LT (1) LT2894162T (hr)
PL (3) PL2433954T3 (hr)
PT (3) PT2894162T (hr)
RS (3) RS53988B1 (hr)
RU (2) RU2485974C2 (hr)
SI (3) SI2433954T1 (hr)
WO (1) WO2007031222A2 (hr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
AU2013206613B2 (en) * 2005-09-12 2017-03-02 Biontech Ag Identification of tumor-associated antigens for diagnosis and therapy
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
AU2016201637B2 (en) * 2007-10-23 2017-05-25 Biontech Ag Identification of tumor-associated markers for diagnosis and therapy
AU2015205868B2 (en) * 2008-09-16 2017-04-27 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
BR112012030794B1 (pt) * 2010-06-04 2019-11-26 Inserm ( Institut National De La Santé Et De La Recherche Médicale) Novos compostos imunoadjuvantes e usos dos mesmos
NZ730355A (en) 2011-05-24 2022-10-28 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Individualized vaccines for cancer
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
SG11201606439VA (en) 2014-02-07 2016-09-29 Dong Wha Pharm Co Ltd Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug
WO2016040682A1 (en) 2014-09-10 2016-03-17 Genentech, Inc. Immunogenic mutant peptide screening platform
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
RU2620306C2 (ru) * 2015-01-15 2017-05-24 Олег Викторович Бухтояров Способ прогнозирования рецидива злокачественного опухолевого заболевания
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016146618A1 (en) * 2015-03-16 2016-09-22 Max-Delbrück-Centrum für Molekulare Medizin Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
CA2989373A1 (en) * 2015-06-16 2016-12-22 Targovax Asa Mutated fragments of the ras protein
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
SG11201804957VA (en) 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
EP3400004A1 (en) 2016-01-08 2018-11-14 Vaccibody AS Therapeutic anticancer neoepitope vaccine
US10712310B2 (en) 2016-01-22 2020-07-14 Temple University—Of the Commonwealth System of Higher Education Protein quantification by near infrared spectral imaging
CN107266552B (zh) * 2016-03-30 2022-02-08 香雪生命科学技术（广东）有限公司 源自于prame的肿瘤抗原短肽
JP6717982B2 (ja) 2016-05-20 2020-07-08 アランセオ・ネザーランズ・ベー・フェー ゴム組成物
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
CN108250289B (zh) * 2016-12-28 2021-10-08 香雪生命科学技术（广东）有限公司 源自于mage b6的肿瘤抗原短肽
TWI676483B (zh) * 2017-08-06 2019-11-11 強普生技股份有限公司 醫藥套組及其用途
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
JP7082556B2 (ja) 2018-09-28 2022-06-08 三和シヤッター工業株式会社 シャッター装置

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) * 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
AU612370B2 (en) * 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
ATE196606T1 (de) * 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5744585A (en) * 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) * 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
MXPA01007148A (es) * 1999-01-13 2002-03-27 Igeneon Krebs Immuntherapie Uso de anticuerpos para vacunacion anti-cancer.
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
AU2001280608A1 (en) * 2000-07-18 2002-01-30 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
IL154751A0 (en) * 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
US20020177547A1 (en) * 2001-01-16 2002-11-28 Karin Molling Pharmaceutical compositions for treating or preventing cancer
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2002097035A2 (en) * 2001-05-25 2002-12-05 Incyte Genomics, Inc. Secreted proteins
CA2457819A1 (en) * 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
WO2003075014A2 (en) * 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
WO2003102159A2 (en) * 2002-06-04 2003-12-11 Curagen Corporation Novel proteins and nucleic acids encoding same
US7053201B2 (en) * 2002-08-30 2006-05-30 National Defense Medical Center Nucleic acid molecules and polypeptides related to h-ADAM7
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
PL218660B1 (pl) 2002-10-17 2015-01-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
AU2003291399A1 (en) * 2002-11-06 2004-06-03 Sequenom, Inc. Methods for identifying risk of melanoma and treatments thereof
JP4624977B2 (ja) * 2003-01-17 2011-02-02 ザ チャイニーズ ユニバーシティ オブ ホンコン 妊娠障害診断マーカーとしての血中ｍＲＮＡ
AU2004210986A1 (en) * 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
WO2005049806A2 (en) * 2003-03-14 2005-06-02 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
RU2256924C2 (ru) * 2003-09-03 2005-07-20 Торопова Надежда Ефимовна Способ дифференциальной диагностики злокачественных опухолей простаты
WO2005079490A2 (en) * 2004-02-13 2005-09-01 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
CN1663603A (zh) * 2004-03-02 2005-09-07 北京大学 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CN107028969A (zh) * 2009-02-20 2017-08-11 加尼梅德药物公司 用于癌症诊断和治疗的方法和组合物
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer

Also Published As

Publication number Publication date
US20110189179A1 (en) 2011-08-04
RS57080B1 (sr) 2018-06-29
CA2820201C (en) 2018-07-17
JP5913547B2 (ja) 2016-04-27
US9919036B2 (en) 2018-03-20
EP2902412A1 (en) 2015-08-05
EP2433955A2 (en) 2012-03-28
WO2007031222A3 (en) 2007-07-26
RU2013113439A (ru) 2014-10-10
EP2433962A2 (en) 2012-03-28
US8975375B2 (en) 2015-03-10
EP2433954B8 (en) 2015-05-13
HK1211606A1 (en) 2016-05-27
AU2006291717B2 (en) 2013-06-06
PT2894162T (pt) 2018-04-02
RS53009B (en) 2014-04-30
EP2433955A3 (en) 2012-07-04
HK1118840A1 (en) 2009-02-20
EP2433962A3 (en) 2012-07-04
JP6037593B2 (ja) 2016-12-07
EP2433959A3 (en) 2012-06-27
CA2620712A1 (en) 2007-03-22
LT2894162T (lt) 2018-04-10
CY1114661T1 (el) 2016-10-05
DK2894162T3 (en) 2018-04-16
ES2532410T3 (es) 2015-03-26
EP1762575A1 (en) 2007-03-14
CY1116951T1 (el) 2017-04-05
EP2902412B1 (en) 2018-02-21
EP2433958A2 (en) 2012-03-28
EP2433960B1 (en) 2015-03-04
JP6196338B2 (ja) 2017-09-13
CY1120096T1 (el) 2018-12-12
BRPI0616827A2 (pt) 2011-07-05
EP2433954B1 (en) 2015-02-25
US20170080068A1 (en) 2017-03-23
DK1924600T3 (da) 2013-11-11
HRP20180507T1 (hr) 2018-05-04
SI1924600T1 (sl) 2013-12-31
CA2820201A1 (en) 2007-03-22
PT2433954E (pt) 2015-06-02
ES2664386T3 (es) 2018-04-19
PL2433954T3 (pl) 2015-07-31
KR20130121198A (ko) 2013-11-05
EP1924600A2 (en) 2008-05-28
AU2006291717A1 (en) 2007-03-22
DK2433954T3 (en) 2015-05-04
RU2485974C2 (ru) 2013-06-27
JP2015120691A (ja) 2015-07-02
EP2433958A3 (en) 2012-07-04
SI2894162T1 (en) 2018-05-31
EP2433957A3 (en) 2012-07-04
JP2016166175A (ja) 2016-09-15
EP2894162B1 (en) 2018-01-03
PL2894162T3 (pl) 2018-06-29
EP2966082A1 (en) 2016-01-13
KR20080052664A (ko) 2008-06-11
JP2009507868A (ja) 2009-02-26
EP2433954A2 (en) 2012-03-28
CN101305020A (zh) 2008-11-12
EP2433960A2 (en) 2012-03-28
EP2433956A3 (en) 2012-07-04
EP2433956A2 (en) 2012-03-28
HK1168608A1 (en) 2013-01-04
US20140017254A1 (en) 2014-01-16
EP2894162A1 (en) 2015-07-15
RS53988B1 (en) 2015-10-30
KR101359697B1 (ko) 2014-02-07
EP2433958B1 (en) 2015-02-25
HUE037307T2 (hu) 2018-08-28
ES2535500T3 (es) 2015-05-12
EP2433962B1 (en) 2015-03-25
EP2433959A2 (en) 2012-03-28
US20090202530A1 (en) 2009-08-13
SI2433954T1 (sl) 2015-06-30
EP2433961A3 (en) 2012-06-27
ES2434945T3 (es) 2013-12-18
RU2008114318A (ru) 2009-10-20
PL1924600T3 (pl) 2014-01-31
CN101305020B (zh) 2015-09-02
EP1924600B1 (en) 2013-08-28
PT1924600E (pt) 2013-11-18
EP2433961A2 (en) 2012-03-28
US20150197576A1 (en) 2015-07-16
HRP20150432T1 (hr) 2015-09-25
RU2644686C2 (ru) 2018-02-13
WO2007031222A2 (en) 2007-03-22
EP2433957A2 (en) 2012-03-28
JP2013136579A (ja) 2013-07-11
EP2433960A3 (en) 2012-07-04
EP2433954A3 (en) 2012-07-04
EP2966082B1 (en) 2017-08-30
JP2016102116A (ja) 2016-06-02
JP5750433B2 (ja) 2015-07-22

Similar Documents

Publication Publication Date Title
HRP20131047T1 (hr) Identifikacija antigena povezanih s tumorom za dijagnozu i lijeäśenje
JP6630766B2 (ja) 膵臓癌診断用組成物およびこれを用いた膵臓癌診断方法
US9255142B2 (en) Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
CN101389958B (zh) 使用轴突导向因子netrin-1的活性筛选抗癌化合物的方法
HRP20100412T1 (hr) Identifikacija površinskih antigena radi dijagnoze i liječenja tumora
US8105598B2 (en) Human monoclonal antibodies that specifically bind IGF-II
KR102210333B1 (ko) 암의 진단용 조성물
WO2019078614A1 (ko) 혈액 내 chi3l1 발현 수준을 이용한 정상압 수두증 진단용 조성물과 진단 마커 검출 방법
JP6847972B2 (ja) 大腸がん診断用組成物と診断マーカー検出方法
US7824681B2 (en) Human monoclonal antibodies that specifically bind IGF-II
JP6361943B2 (ja) 補体因子ｂタンパク質に特異的に結合する抗体及び糖鎖抗原１９−９タンパク質に特異的に結合する抗体を含む膵臓癌診断用キット
RU2007104925A (ru) СПОСОБЫ ЛЕЧЕНИЯ РАКА С ПРИМЕНЕНИЕМ АГЕНТОВ, КОТОРЫЕ ИНГИБИРУЮТ СИГНАЛЬНЫЙ ПУТЬ Wnt16
JP2003521244A5 (hr)
JP2005520543A5 (hr)
KR102058150B1 (ko) 담도 세포에서 메티오닐-티알엔에이 합성효소를 이용한 담도암 진단 방법
KR102216386B1 (ko) 암의 진단용 조성물
KR102433986B1 (ko) 암의 진단용 조성물
KR102433983B1 (ko) 암의 진단용 조성물
KR102325742B1 (ko) 암의 진단용 조성물
KR101901457B1 (ko) 간암 암 줄기세포 특성에 기초한 간암의 신규 바이오마커 및 그의 용도
JP2012525121A5 (hr)
KR101594287B1 (ko) 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트
KR20230030228A (ko) 암의 진단용 조성물
IL266576B1 (en) Antibodies that uniquely bind the PAUF protein and their uses
KR20180132376A (ko) 대장암 진단 마커로서의 신규 folr2 융합유전자 및 이의 용도